Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Extracellular adenosine is elevated in cancer tissue, and it negatively regulates local immune responses. Adenosine production from extracellular ATP has attracted attention as a mechanism of regulatory T cell-mediated immune regulation. In this study, we examined whether small vesicles secreted by cancer cells, called exosomes, contribute to extracellular adenosine production and hence modulate immune effector cells indirectly. We found exosomes from diverse cancer cell types exhibit potent ATP- and 5'AMP-phosphohydrolytic activity, partly attributed to exosomally expressed CD39 and CD73, respectively. Comparable levels of activity were seen with exosomes from pleural effusions of mesothelioma patients. In such fluids, exosomes accounted for 20% of the total ATP-hydrolytic activity. Exosomes can perform both hydrolytic steps sequentially to form adenosine from ATP. This exosome-generated adenosine can trigger a cAMP response in adenosine A(2A) receptor-positive but not A(2A) receptor-negative cells. Similarly, significantly elevated cAMP was also triggered in Jurkat cells by adding exosomes with ATP but not by adding exosomes or ATP alone. A proportion of healthy donor T cells constitutively express CD39 and/or CD73. Activation of T cells by CD3/CD28 cross-linking could be inhibited by exogenously added 5'AMP in a CD73-dependent manner. However, 5'AMP converted to adenosine by exosomes inhibits T cell activation independently of T cell CD73 expression. This T cell inhibition was mediated through the adenosine A(2A) receptor. In summary, the data highlight exosome enzymic activity in the production of extracellular adenosine, and this may play a contributory role in negative modulation of T cells in the tumor environment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clayton et al. reported the expression of CD39, CD73, and eADO in MPM-derived exosome from pleural effusion, contributing to the inhibition of T cell functions [133].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [133]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids
Théry, C., Amigorena, S., Raposo, G., & Clayton, A. (2006) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0322s30 · Cited by 5,766 · cited 1×
“To quantify the density of exosomes, we used a protocol similar to that previously described, based on ultracentrifugation on a linear sucrose gradient (36).”
MethodSelf-citationMembrane vesicles as conveyors of immune responses
Théry, C., Ostrowski, M., & Segura, E. (2009) · Nature Reviews Immunology · doi:10.1038/nri2567 · Cited by 3,882 · cited 1×
“immune-activating functions, there are also accumulating data pointing to varied suppressive effects (40).”
BackgroundB lymphocytes secrete antigen-presenting vesicles.
Raposo, G., Nijman, H. W., Stoorvogel, W., Liejendekker, R., Harding, C. V., Melief, C. J., & Geuze, H. J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.1161 · Cited by 3,546 · cited 1×
“The density (g/ml) of each fraction was calculated from the published table in the Beckman Ultracentrifugation catalogue as described (37).”
MethodDeaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J.-F., Enjyoji, K., Linden, J., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,470 · cited 5×
“These are double-positive for CD39 and CD73 in mice (12) and according to one report also in human (45).”
BackgroundInfluentialOhta, A., & Sitkovsky, M. (2001) · Nature · doi:10.1038/414916a · Cited by 1,334
Borsellino, G., Kleinewietfeld, M., Di Mitri, D., Sternjak, A., Diamantini, A., Giometto, R., Höpner, S., Centonze, D., Bernardi, G., Dell'Acqua, M. L., et al. (2007) · Blood · doi:10.1182/blood-2006-12-064527 · Cited by 1,286 · cited 3×
“Natural regulatory T cells of mice express both CD39 and CD73, whose coordinated enzymatic actions produce adenosine as a mechanism for immune suppression that is independent of IL-10 and TGF-b (12, 13).”
BackgroundAdenosine receptors: therapeutic aspects for inflammatory and immune diseases
Haskó, G., Linden, J., Cronstein, B., & Pacher, P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2638 · Cited by 1,217 · cited 1×
“mechanisms involved in adenosine formation and subsequent signaling are therefore of considerable therapeutic interest (9).”
BackgroundA2A adenosine receptor protects tumors from antitumor T cells
Ohta, A., Gorelik, E., Prasad, S. J., Ronchese, F., Lukashev, D., Wong, M. K. K., Huang, X., Caldwell, S., Liu, K., Smith, P., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605251103 · Cited by 1,065 · cited 1×
“Adenosine also represses immune responses in the tumor microenvironment, assisting tumor immune evasion (7, 8).”
BackgroundMalignant effusions and immunogenic tumour-derived exosomes
Andre, F., Schartz, N. E., Movassagh, M., Flament, C., Pautier, P., Morice, P., Pomel, C., Lhomme, C., Escudier, B., Le Chevalier, T., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09552-1 · Cited by 953 · cited 7×
“The cushion was collected and exosomes washed in PBS (32, 34, 35).”
MethodInfluentialExoCarta: A compendium of exosomal proteins and RNA
Mathivanan, S., & Simpson, R. J. (2009) · PROTEOMICS · doi:10.1002/pmic.200900351 · Cited by 873
Cited by
Items 201–300 of 564
T cell-derived exosomes in tumor immune modulation and immunotherapy
Zhou, Q., Wei, S., Wang, H., Li, Y., Fan, S., Cao, Y., & Wang, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1130033 · Cited by 51
“This study was funded by the GK2021 Provincial Natural Fund (21-262) (grant no.”
MethodConter, L. J., Song, E., Shlomchik, M. J., & Tomayko, M. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092009 · Cited by 55
“tion [15–17].”
Elashiry, M., Elsayed, R., & Cutler, C. W. (2021) · Cells · doi:10.3390/cells11010115 · Cited by 61
Salmond, N., & Williams, K. C. (2021) · Nanoscale Advances · doi:10.1039/d0na00676a · Cited by 61
Tumor Microenvironment and Hydrogel-Based 3D Cancer Models for In Vitro Testing Immunotherapies
Vitale, C., Marzagalli, M., Scaglione, S., Dondero, A., Bottino, C., & Castriconi, R. (2022) · Cancers · doi:10.3390/cancers14041013 · Cited by 62
“Moreover, it has been reported that tumor cells and tumor-derived exosomes can carry CD39 and CD73 on their membranes, thus promoting ATP conversion and adenosine accumulation in the TME [120,121].”
BackgroundTortajada, M., Roura, S., Gálvez‐Montón, C., Franquesa, M., Bayés‐Genís, A., & Borràs, F. E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01577 · Cited by 60
“It further proves to be a powerful systemic immunosuppressant as Ado production is used as an immune evasion strategy by pathogens (36–38) and cancer cells (8, 39, 40), and its accumulation leads to a severe combined immunodeficiency in patients lacking ADA for Ado degradation (41, 42).”
BackgroundCaffeine: Well-known as psychotropic substance, but little as immunomodulator
Reef, T. A., & Ghanem, E. (2018) · Immunobiology · doi:10.1016/j.imbio.2018.08.011 · Cited by 57
Tumor-derived nanoseeds condition the soil for metastatic organotropism
Hu, M., Kenific, C. M., Boudreau, N. J., & Lyden, D. C. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.05.003 · Cited by 59
Klein‐Scory, S., Tehrani, M. M., Eilert-Micus, C., Adamczyk, K. A., Wojtalewicz, N., Schnölzer, M., Hahn, S. A., Schmiegel, W., & Schwarte‐Waldhoff, I. (2014) · Proteome Science · doi:10.1186/s12953-014-0050-5 · Cited by 57
“NT5E/CD73 which catalyses the release of adenosine [42].”
BackgroundTumor-Derived Exosomes: Hidden Players in PD-1/PD-L1 Resistance
Vautrot, V., Bentayeb, H., Causse, S., Garrido, C., & Gobbo, J. (2021) · Cancers · doi:10.3390/cancers13184537 · Cited by 58
“Exosomes naturally bear CD73 and CD39, and the proteins are present in exosomes isolated from the plasma or pleural fluid of cancer patients (bladder, breast, prostate cancers, mesothelioma, HNSCC, and adenocarcinoma) [76,78,79].”
BackgroundInfluentialTargeting T cell exhaustion: emerging strategies in non-small cell lung cancer
Liu, X., Xi, X., Xu, S., Chu, H., Hu, P., Li, D., Zhang, B., Liu, H., Jiang, T., & Lu, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1507501 · Cited by 57
Izzi, V., Masuelli, L., Tresoldi, I., Foti, C., Modesti, A., & Bei, R. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.02.034 · Cited by 60
Kumar, A., Zhou, L., Zhi, K., Raji, B., Pernell, S., Tadrous, E., Kodidela, S., Nookala, A. R., Kochat, H., & Kumar, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010138 · Cited by 56
“Tumor-derived exosomes can negatively regulate T cell immunity by raising adenosine levels when expressing CD39 and CD73 [188].”
BackgroundExosomes as emerging players in cancer biology
Couto, N., Caja, S., Maia, J., Moraes, M. C. S., & Costa‐Silva, B. (2018) · Biochimie · doi:10.1016/j.biochi.2018.03.006 · Cited by 56
Immune Suppressive Effects of Plasma-Derived Exosome Populations in Head and Neck Cancer
Beccard, I. J., Hofmann, L., Schroeder, J. C., Ludwig, S., Laban, S. A., Brunner, C., Lotfi, R., Hoffmann, T. K., Jackson, E. K., Schuler, P. J., et al. (2020) · Cancers · doi:10.3390/cancers12071997 · Cited by 54
“The presence of adenosine in the TME of HNSCC has been linked to tumor progression and poor outcome [9].”
BackgroundInfluentialRole of tumour-derived exosomes in metastasis
Bai, S., Wei, Y., Liu, R., Xu, R., Li, X., & Du, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112657 · Cited by 56
Exosomes: New insights into cancer mechanisms
Sahebi, R., Langari, H., Fathinezhad, Z., Sani, Z. B., Avan, A., Ghayour‐Mobarhan, M., & Rezayi, M. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29120 · Cited by 53
“Research has shown that breast, colon, bladder, and prostate cancer cells, CD39 and CD73, which act as enzymes, they appear on the surface of their exosomes and through the production of suppressor adenosine, affect the function of T cells.(56) Another way to regulating immune cells is the secretion of vesicles in the…”
BackgroundThe role of the CD39–CD73–adenosine pathway in liver disease
Wang, S., Gao, S., Zhou, D., Qian, X., Luan, J., & Lv, X. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29932 · Cited by 55
Role of Acute Myeloid Leukemia (AML)-Derived exosomes in tumor progression and survival
Amin, A. H., Sharifi, L. M. A., Kahharov, A., Opulencia, M. J. C., Alsaikhan, F., Bokov, D. O., Majdi, H. S., Jawad, M. A., Hammid, A. T., Shalaby, M. N., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113009 · Cited by 57
The Multifaceted Actions of CD73 During Development and Suppressive Actions of Regulatory T Cells
Da, M., Chen, L., Enk, A., Ring, S., & Mahnke, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.914799 · Cited by 52
“EVs derived from different cancer cell lines express CD73 and catalyze AMP to ado (83).”
BackgroundKhan, N. A., Asim, M., Biswas, K. H., Alansari, A. N., Saman, H. T., Sarwar, M. Z., Osmonaliev, K., & Shahab Uddin, M. S. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02753-7 · Cited by 51
“TEXs have surface CD39 and CD73 and directly distribute membrane-tethered CD73 to CD39 + cells [132].”
BackgroundSáez, T., de Vos, P., Sobrevía, L., & Faas, M. M. (2017) · Placenta · doi:10.1016/j.placenta.2017.11.007 · Cited by 54
Spatola, B. N., Lerner, A. G., Wong, C., Cruz, T. D., Welch, M., Fung, W., Kovalenko, M. A., Losenkova, K., Yegutkin, G. G., Beers, C., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1838036 · Cited by 52
Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy
Buqué, A., Bloy, N., Aranda, F., Cremer, I., Eggermont, A. M. M., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., Tartour, É., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1149674 · Cited by 51
“The pharmacological inhibition of CD39 and/or CD73 has been shown to promote therapeutically relevant tumor-targeting immune responses in several rodent models of oncogenesis and tumor progression.(147,152-163) None of these agents, however, has yet entered clinical evaluation for its”
BackgroundFunctional role of extracellular vesicles and lipoproteins in the tumour microenvironment
Menard, J. A., Cerezo-Magaña, M., & Belting, M. (2017) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2016.0480 · Cited by 53
Deng, W., Li, Y., Ma, S., Mao, L., Yu, G., Bu, L., Kulkarni, A. B., Zhang, W., & Sun, Z. (2018) · International Journal of Cancer · doi:10.1002/ijc.31534 · Cited by 51
Revisiting the Role of Exosomes in Colorectal Cancer: Where Are We Now?
Mannavola, F., Salerno, T., Passarelli, A. M., Tucci, M., Internò, V., & Silvestris, F. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00521 · Cited by 54
“In this regard, it has been demonstrated that Exos derived from different cancer cells including bladder, prostate and colorectal tumors, express both CD39 and CD73 ecto-nucleotidases (42) that are involved in the adenosine triphosphate (ATP)-dephosphorylation to adenosine (43).”
BackgroundTargeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer
Allard, B., Turcotte, M., & Stagg, J. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.915315 · Cited by 46
“Last but not the least, CD73 and its ATP-hydrolyzing partner CD39 have recently been shown to be expressed at the surface of exosomes released by several cancer cell lines or present in pleural effusions of mesothelioma patients [117].”
BackgroundSáenz-Cuesta, M., Alberro, A., Muñoz‐Culla, M., Osorio-Querejeta, I., Fernández‐Mercado, M., Lopetegui, I., Tainta, M., Prada, A. J., Castillo‐Triviño, T., Falcón‐Pérez, J. M., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082448 · Cited by 50
“This role has been demonstrated for other EV subtypes, such as those derived from breast milk [20] or cancer cell lines [21] and moreover, Kimura et al.”
BackgroundMartínez-Ramírez, A. S., Díaz‐Muñoz, M., Butanda-Ochoa, A., & Vázquez‐Cuevas, F. G. (2016) · Purinergic Signalling · doi:10.1007/s11302-016-9550-3 · Cited by 48
Li, P., Feng, J., Liu, Y., Liu, Q., Fan, L., Liu, Q., She, X., Liu, C., Liu, T., Zhao, C., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01748 · Cited by 50
Emerging Role of Exosomes in Diagnosis and Treatment of Infectious and Inflammatory Bowel Diseases
Larabi, A. B., Barnich, N., & Nguyen, H. T. T. (2020) · Cells · doi:10.3390/cells9051111 · Cited by 49
“These exosomes may carry the CD39 and CD73 surface proteins, which induce the production of adenosine, a nucleotide that plays a major role in anti-inflammatory response and T cell suppression [70], and transport the miRNA let-7d that suppresses T helper (Th) 1 proliferation and cytokine secretion, thus mediating immu…”
BackgroundImplications of CD39 in immune-related diseases
Zeng, J., Ning, Z., Zhang, H., Dong, G., Zhang, J., Shi, H., Yan, F., Zhao, M., Wang, C., Ma, Q., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107055 · Cited by 51
Role of exosomes in the immune microenvironment of ovarian cancer (Review)
Xiao, L., Liu, Y., Zheng, S., Zhang, T., Wu, J., Sun, Y., Zhang, J., & Liu, G. (2021) · Oncology Letters · doi:10.3892/ol.2021.12638 · Cited by 48
Hennel, R., Brix, N., Seidl, K., Ernst, A., Scheithauer, H., Belka, C., & Lauber, K. (2014) · Radiation Oncology · doi:10.1186/1748-717x-9-85 · Cited by 50
“of CD39 in MCF7 cells has already been reported by others, but the mechanisms, which account for the differences in CD39 expression compared to HCC1937 and BT474 cells, are poorly understood [48].”
A Snapshot of The Tumor Microenvironment in Colorectal Cancer: The Liquid Biopsy
Herrera, M., Galindo-Pumariño, C., García‐Barberán, V., & Peña, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236016 · Cited by 50
“Moreover, in colorectal tumors, as well as in bladder, prostate and breast tumors, T-cells are also negatively regulated by the contribution of exosomal adenosine, which mediates the immune response in the tumor microenvironment [47].”
BackgroundLee, J. J., Jeong, H. J., Kim, M. K., Wee, W. R., Lee, W., Kim, S. U., Sung, C., & Yang, Y. (2013) · Purinergic Signalling · doi:10.1007/s11302-013-9385-0 · Cited by 46
“The immunosuppressive activity of adenosine is well-known in T regulatory cells and in the tumor microenvironment [10, 11].”
The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine
Passarelli, A. M., Tucci, M., Mannavola, F., Felici, C., & Silvestris, F. (2019) · Tumor Biology · doi:10.1177/1010428319837138 · Cited by 46
Grage‐Griebenow, E., Jerg, E., Gorys, A., Wicklein, D., Wesch, D., Freitag‐Wolf, S., Goebel, L., Vogel, I., Becker, T., Ebsen, M., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.03.001 · Cited by 51
Cancer-derived extracellular vesicles: friend and foe of tumour immunosurveillance
Dörsam, B., Reiners, K. S., & von Strandmann, E. P. (2018) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2016.0481 · Cited by 44
Signaling of Tumor-Derived sEV Impacts Melanoma Progression
Zebrowska, A., Widlak, P., Whiteside, T. L., & Pietrowska, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145066 · Cited by 44
Exosomes and ultrasound: The future of theranostic applications
Sridharan, B., & Lim, H. G. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100556 · Cited by 49
Exosomes in Severe Asthma: Update in Their Roles and Potential in Therapy
Mortaz, E., Alipoor, S. D., Varahram, M., Jamaati, H., Garssen, J., Mumby, S. E., & Adcock, I. M. (2018) · BioMed Research International · doi:10.1155/2018/2862187 · Cited by 44
Regulatory T cells and potential inmmunotherapeutic targets in lung cancer
Zhang, D., Chen, Z., Wang, D. C., & Wang, X. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9566-0 · Cited by 43
Do, J., Zwick, D. B., Kenyon, J. D., Zhong, F., Askew, D., Huang, A. Y.-C., Hof, W. V., Finney, M. R., & Laughlin, M. J. (2021) · Scientific Reports · doi:10.1038/s41598-021-90115-8 · Cited by 43
Biocompatibility and biodistribution of matrix-bound nanovesicles in vitro and in vivo
Crum, R. J., Capella-Monsonís, H., Chang, J., Dewey, M. J., Kolich, B. D., Hall, K. T., El-Mossier, S. O., Nascari, D. G., Hussey, G. S., & Badylak, S. F. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.11.026 · Cited by 42
Exosomes: Powerful weapon for cancer nano-immunoengineering
Pi, Y., Xia, B.-R., Jin, M., Jin, W., & Lou, G. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114487 · Cited by 43
Mesothelioma Malignancy and the Microenvironment: Molecular Mechanisms
Cersosimo, F., Barbarino, M., Lonardi, S., Vermi, W., Giordano, A., Bellan, C., & Giurisato, E. (2021) · Cancers · doi:10.3390/cancers13225664 · Cited by 41
Exosome-derived proteins in gastric cancer progression, drug resistance, and immune response
Wang, J., Zhang, H., Li, J., Ni, X., Yan, W., Chen, Y., & Shi, T. (2024) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00676-5 · Cited by 43
The Effect of the Tumor Microenvironment and Tumor-Derived Metabolites on Dendritic Cell Function
Lee, J., Choi, S.-Y., Jung, N.-C., Song, J. Y., Seo, H. G., Lee, H. S., & Lim, D. (2019) · Journal of Cancer · doi:10.7150/jca.38785 · Cited by 43
“adenosine at the cancer interface [40].”
Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma
Tripathi, A., Lin, E., Xie, W., Flaifel, A., Steinharter, J. A., Gatof, E. S., Bouchard, G., Fleischer, J. H., Chanzá, N. M., Gray, C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001467 · Cited by 44
Interplay between purinergic signalling and extracellular vesicles in health and disease
Carotti, V., Rigalli, J. P., van der Wijst, J., & Hoenderop, J. G. J. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115192 · Cited by 42
Abernathy, J. W., Brezas, A., Snekvik, K. R., Hardy, R. W., & Overturf, K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180972 · Cited by 42
High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma
Zhang, B., Cheng, B., Li, F., Ding, J., Feng, Y., Zhuo, G., Wei, H., & Zhao, K. (2015) · Tumor Biology · doi:10.1007/s13277-015-3683-9 · Cited by 40
Fiorilla, I., Martinotti, S., Todesco, A. M., Bonsignore, G., Cavaletto, M., Patrone, M., Ranzato, E., & Audrito, V. (2023) · Cells · doi:10.3390/cells12162048 · Cited by 39
Mallardo, D., Fordellone, M., White, A. M., Ottaviano, M., Sparano, F., Bailey, M. D., Facchini, A. B., Ong, S., Maiolino, P., Caracò, C., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04419-6 · Cited by 40
“7 Accuracy of gene selection, through latent score, for high NLR post /NLR baseline anti-tumor functions mediated by T cells and NK cells [22].”
BackgroundExosome therapeutics for non-small cell lung cancer tumorigenesis
Orooji, N., Fadaee, M., Kazemi, T., & Yousefi, B. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03544-6 · Cited by 41
“For instance, it has been demonstrated that Treg cells release exosomes that express CD73 and prohibit the growth of CD4 + T cells [97].”
BackgroundRole and Function of T Cell‐Derived Exosomes and Their Therapeutic Value
Shao, Y., Pan, X., & Fu, R. (2021) · Mediators of Inflammation · doi:10.1155/2021/8481013 · Cited by 39
“This has been veri fi ed in a preclinical study, which showed its relative safety [58].”
Gargiulo, E., Viry, E., Morande, P. E., Largeot, A., Gonder, S., Xian, F., Ioannou, N., Benzarti, M., Borgmann, F. B. K., Mittelbronn, M. G. A., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-22-0029 · Cited by 41
“We confirmed that treatment of CD8+ T cells with ATP and CD39+LME-sEVs decreased proliferation, cytotoxicity, and IL2/GzmB production (31, 43).”
BackgroundLu, D., & Insel, P. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.466102 · Cited by 42
Hydrolysis of ATP, ADP, and AMP is increased in blood plasma of prostate cancer patients
Gardani, C. F. F., Cappellari, A. R., de Souza, J. B., Tertuliano, B., Engroff, P., Moritz, C. E. J., Scholl, J. N., Battastini, A. M. O., Figueiró, F., & Morrone, F. B. (2019) · Purinergic Signalling · doi:10.1007/s11302-018-9642-3 · Cited by 39
“Clayton and collaborators have shown that the supernatant of different kinds of tumor cells secreted exosomes with CD39 and CD73 activity, which modulated the isolated T-cells [19].”
BackgroundExosomes and GPI-anchored proteins: Judicious pairs for investigating biomarkers from body fluids
Vidal, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.08.006 · Cited by 41
Exosomes in review: A new frontier in CAR-T cell therapies
Wang, J. S., Schellenberg, S., Demeros, A., & Lin, A. Y. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101147 · Cited by 39
“The pathway of adenosine generation is dependent on tumor-derived exosomes expressing CD39 and CD73 jumpstarting the conversion of 5 ′ AMP to adenosine which is toxic to immune cells [66,67].”
Plasma-derived candidate biomarkers for detection of gallbladder carcinoma
Priya, R., Jain, V., Akhtar, J., Chauhan, G., Sakhuja, P., Goyal, S., Agarwal, A., Javed, A., Jain, A., Polisetty, R. V., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-02923-7 · Cited by 36
Tumor-Derived Microvesicles and the Cancer Microenvironment
Camussi, G., Deregibus, M. C., & Tetta, C. (2012) · Current Molecular Medicine · doi:10.2174/1566524011307010058 · Cited by 36
Turner, R. J., Geraghty, N. J., Williams, J. G., Ly, D., Brungs, D., Carolan, M., Guy, T. V., Watson, D., de Leon, J. F., & Sluyter, R. (2020) · Purinergic Signalling · doi:10.1007/s11302-020-09714-1 · Cited by 36
García‐Cañaveras, J. C., & Lahoz, A. (2021) · Cancers · doi:10.3390/cancers13133230 · Cited by 38
Tumor-Derived Microvesicles and the Cancer Microenvironment
Camussi, G., Deregibus, M. C., & Tetta, C. (2012) · Current Molecular Medicine · doi:10.2174/156652413804486304 · Cited by 43
Khan, F. H., Reza, M. J., Shao, Y. F., Perwez, A., Zahra, H., Dowlati, A., & Abbas, A. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188776 · Cited by 36
The landscape of non-coding RNAs in the immunopathogenesis of Endometriosis
Abbaszadeh, M., Karimi, M., & Rajaei, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1223828 · Cited by 37
Exosomal microRNAs (exoMIRs): micromolecules with macro impact in oral cancer
Dhar, R., Mallik, S., & Devi, A. (2022) · 3 Biotech · doi:10.1007/s13205-022-03217-z · Cited by 36
Clinical Impact of Exosomes in Colorectal Cancer Metastasis
Ghosh, S., Dhar, R., Shivji, G. G., Dey, D., Devi, A., Jha, S. K., Adhikari, M. D., & Gorai, S. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00199 · Cited by 36
Cancer cells use exosomes as tools to manipulate immunity and the microenvironment
Clayton, A. (2012) · OncoImmunology · doi:10.4161/onci.1.1.17826 · Cited by 35
“Hence exosomes have the capacity to exosomes, that may be driven sequentially by surface bound CD39 and CD73 and likely also other exosomal constituents, to form adenosine.(8) Like TGFβ expression, this is indeed a property which is present on exosomes isolated directly from tumor possibility whereby exosomes may modu…”
BackgroundSelf-citationRole of exosomes in tumour and transplant immune regulation
Lema, D. A., & Burlingham, W. J. (2019) · Scandinavian Journal of Immunology · doi:10.1111/sji.12807 · Cited by 35
Regulation of Antitumor Immune Responses by Exosomes Derived from Tumor and Immune Cells
Rincón‐Riveros, A., López, L., Villegas, V. E., & Rodríguez, J. A. (2021) · Cancers · doi:10.3390/cancers13040847 · Cited by 36
“In cancer cell lines (bladder, colorectal, prostate and breast) exosomes expressing CD39 and CD73 ectonucleotidases have been described that can indirectly modulate the effector immune cells activity in the tumor environment as a mechanism of Treg cell-mediated immune regulation, [51].”
BackgroundHofmann, L., Medyany, V., Ezić, J., Lotfi, R., Niesler, B., Röth, R., Engelhardt, D., Laban, S. A., Schuler, P. J., Hoffmann, T. K., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.904295 · Cited by 37
“Exosomes strongly contribute to an immunosuppressive tumor microenvironment (TME) and play a prominent role in immune evasion (3, 4).”
BackgroundInfluentialRoefs, M. T., Bauzá‐Martinez, J., van de Wakker, S. I., Qin, J., Olijve, W. T., Tuinte, R., Rozeboom, M., Blok, C. S., Mol, E. A., Wu, W., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05165-7 · Cited by 37
The Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review
Désage, A.-L., Karpathiou, G., Peoc’h, M., & Froudarakis, M. E. (2021) · Cancers · doi:10.3390/cancers13133205 · Cited by 34
Extracellular vesicles: biogenesis mechanism and impacts on tumor immune microenvironment
Yeat, N. Y., & Chen, R. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01182-2 · Cited by 35
“Similarly, EVs isolated from head and neck cancer and bladder cancer carry high levels of CD39 and CD73, which facilitate adenosine generation to support Tregs pro-tumor functions [132, 133].”
Wu, Z., Yang, L., Shi, L., Hu, S., Shi, P.-C., Yang, T., Fan, R., Jiang, T., & Song, J. (2019) · BioMed Research International · doi:10.1155/2019/8014627 · Cited by 41
“Previous studies have shown A2aR signaling inhibits the function of multiple immune subsets, including T cells and NK cells [40].”
BackgroundCharacterization and Antiproliferative Activity of Glioma-Derived Extracellular Vesicles
Scholl, J. N., Dias, A. D. F., Pizzato, P. R., Lopes, D. V., Moritz, C. E. J., Jandrey, E. H. F., Souto, G. D., Colombo, M., Rohden, F., Sévigny, J., et al. (2020) · Nanomedicine · doi:10.2217/nnm-2019-0431 · Cited by 34
CD73: A Promising Biomarker in Cancer Patients
Turiello, R., Pinto, A., & Morello, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.609931 · Cited by 34
“Notably, CD73 expressed on exosomes maintains its enzymatic activity, and the exosome-derived adenosine is responsible of T-cell inhibition and impaired antitumor immune response (Clayton et al., 2011; Schuler et al., 2014; Ludwig et al., 2017; Zhang et al., 2019).”
BackgroundLiu, G., Zhang, Q., Liu, G., Li, D., Zhang, L., Gu, Z., Tian, H., Zhang, Y., & Tian, X. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112886 · Cited by 35
The Skewed Balance Between Tregs and Th17 in Chronic Lymphocytic Leukemia
Yousefi, M., Movassaghpour, A. A., Shamsasenjan, K., Ghalamfarsa, G., Sadreddini, S., Jadidi‐Niaragh, F., & Hojjat‐Farsangi, M. (2015) · Future Oncology · doi:10.2217/fon.14.298 · Cited by 39
Metabolic Signaling in the Tumor Microenvironment
Clay, R., Li, K., & Jin, L. (2025) · Cancers · doi:10.3390/cancers17010155 · Cited by 36
Extracellular vesicles as biomarkers in malignant pleural mesothelioma: A review
Ahmadzada, T., Kao, S., Reid, G., Clarke, S. J., Grau, G. E., & Hosseini‐Beheshti, E. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102949 · Cited by 35
Adenosine Signaling in the Tumor Microenvironment
Antonioli, L., Fornai, M., Pellegrini, C., D’Antongiovanni, V., Turiello, R., Morello, S., Haskó, G., & Blandizzi, C. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-47189-7_9 · Cited by 33
Najaflou, M., Shahgolzari, M., Khosroushahi, A. Y., & Fiering, S. (2022) · Cancers · doi:10.3390/cancers15010082 · Cited by 34
Wang, Y., Liu, M., Zhang, L., Liu, X., Ji, H., Wang, Y., Gui, J., Yan, Y., & Wen, Z. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06336-4 · Cited by 33
Tadokoro, H., Hirayama, A., Kudo, R., Hasebe, M., Yoshioka, Y., Matsuzaki, J., Yamamoto, Y., Sugimoto, M., Soga, T., & Ochiya, T. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231430 · Cited by 32
Exosomes: Small EVs with Large Immunomodulatory Effect in Glioblastoma
Benecke, L., Coray, M., Umbricht, S., Chiang, D. M., Figueiró, F., & Müller, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073600 · Cited by 33
“The ectoenzymes CD39 and CD73 are found, not only on hematopoietic (mesenchy‐ mal stromal cells), cancer, and B cells [76], but also on tumor exosomes [77].”
BackgroundTumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment
Laubach, K., Turan, T., Mathew, R. S., Wilsbacher, J. L., Engelhardt, J., & Samayoa, J. A. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.60 · Cited by 33
Functional Roles and Therapeutic Applications of Exosomes in Hepatocellular Carcinoma
Santangelo, L., Battistelli, C., Montaldo, C., Citarella, F., Strippoli, R., & Cicchini, C. (2017) · BioMed Research International · doi:10.1155/2017/2931813 · Cited by 32
“One proposed mechanism for T cell suppression is the extracellular adenosine production by exosomes exposing CD39 and CD37 on their surface [29].”
BackgroundExtracellular vesicles in cancer immune responses: roles of purinergic receptors
Graner, M. W. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0706-9 · Cited by 32
Shi, J.-H., Ren, Y., Zhen, L., & Qiu, X. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2749 · Cited by 35
“…number of studies have indicated diverse immunosuppressive effects of exosomes from tumor cells, including suppression of effector T cell activity (5), induction of apoptosis in activated T cells (6) and natural killer cells (7), modulation of differentiation in myeloid cells (8), and functional…”
Guzmán‐Flores, J. M., Cortez-Espinosa, N., Cortés-García, J. D., Morales, J. M. V., Cataño, Y., Rodríguez-Rivera, J. G., & Portales‐Pérez, D. P. (2015) · Immunobiology · doi:10.1016/j.imbio.2015.02.007 · Cited by 31
Hong, B., Chapa, V. A., Saini, U., Modgil, P., Cohn, D. E., He, G., Siddik, Z. H., Sood, A. K., Yan, Y., Selvendiran, K., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2210 · Cited by 31
“For example, while tumor-derived exosomes have been shown to enhance antigen presentation by DCs in vitro (47), they also carry immunosuppressive ectoenzymes such as CD73 which can suppress T-cell activation (48).”
BackgroundStimulation of exosome biogenesis by adiponectin, a circulating factor secreted from adipocytes
Kita, S., & Shimomura, I. (2020) · The Journal of Biochemistry · doi:10.1093/jb/mvaa105 · Cited by 31
Ploeg, E. M., Ke, X., Britsch, I., Hendriks, M. A. J. M., van der Zant, F. A., Kruijff, S., Samplonius, D. F., Zhang, H., & Helfrich, W. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.037 · Cited by 30
Modifying exosome release in cancer therapy: How can it help?
Moloudizargari, M., Asghari, M. H., & Abdollahi, M. R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.07.001 · Cited by 30
Metadata
- Authors
- Clayton, A., Al-Taei, S., Webber, J., Mason, M. D., & Tabi, Z.
- Affiliations
- Velindre Cancer Centre (GB)
- Department of Pharmacology, Radiology and Oncology, School of Medicine, Cardiff University, Velindre Cancer Centre , Whitchurch, Cardiff CF14 2TL ,
- Corresponding author
- Clayton, Aled
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-07
- Volume
- 187
- Issue
- 2
- Pages
- 676-683
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2153092839
- Cited by
- 540
- References
- 49
- Citations by year
- 2026: 18 · 2025: 30 · 2024: 31 · 2023: 38 · 2022: 53 · 2021: 50 · 2020: 61 · 2019: 37 · 2018: 36 · 2017: 29 · 2016: 30 · 2015: 24 · 2014: 33 · 2013: 26 · 2012: 40
- FWCI
- 23.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- tumor-derived exosomes, CD39, CD73, extracellular adenosine, ATP hydrolysis, 5'-AMP, adenosine A2A receptor, cAMP signaling, T cell activation inhibition, tumor immunosuppression, mesothelioma, extracellular vesicles
- MeSH terms
- Adenosine, Adenosine Monophosphate, Adenosine Triphosphate, Apyrase, Humans, Hydrolysis, Mesothelioma, Phosphorylation, Pleural Neoplasms, Down-Regulation, Antigens, CD, 5'-Nucleotidase, Caco-2 Cells, Jurkat Cells, Cell Line, Tumor, T-Lymphocytes, Regulatory, Exosomes, GPI-Linked Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.